“93% increase!!!” .. the $ don’t even begin to cover the office electric bill much less Rubin’s salary.. again to reiterate.. cut the price to GENERATE REVENUE not tout percentages which mean nothing relative to your ROI … problems w/3rd party payers?? what’s the breakdown in VA usage; what about jails what about HMOS (no 3rd party pay problems there); what about Knight sales in Canada.. Rubin spun generalities about the new Braeburn CEO from Teva.. anyone notice TEVA price lately, boy did they stumble strategically!.. Braeburn focused on depot & will find itself @ competitive disadvantage to indivior & ALKS…. What have you done Marc, Sunil & Kate to address these issues???? Braeburn is not beholden to the stockholders YOU ARE… oh the BOARD is “supportive”? Who exactly do they support.. for sure not the stockholders.... re: ROW…Kate: “we continue to make progress in our efforts to advance the regulatory review process of Probuphine in Europe”.. what happened to Australia?.. INVVY touted their planned market penetration there & elsewhere.. from INVVY CC: ” You may also remember that we interacted with a lot of ex-U.S. regulatory agencies. So we met in November-December 2016 with the TGA in Australia, Health Canada in Canada, ANSM in France, MHRA in the United Kingdom and MPA in Sweden and BfArM in Germany. Our priority right now is to submit our filing in Canada in the fourth quarter of this year´…. what exactly has TTNP accomplished in the past YEAR to access ROW?...Kate’s response: “Overall, we received strong support for our application and we're on track to submit it to the EMA later this year”… notice any difference between INVVY’s CEO update and Kate’s?.. does the BOARD question any of you 3 managers on what you r doing to enhance shareholder value? Ropinirole.. submitted NDA in Jan…Kate’s words from last CC: "Titan received verbal communication in February ...requesting additional information from us on the final release test data on the implant and on the applicator before the clinical trial proceeds... we expect to submit the requested information by the end of next month" .. so what took you so long to correct deficiency in a timely manner?… did the BOARD ASK THAT QUESTION?... oh I know, you were busy spending R&D on trial balloons like non clinical studies for malaria which you expect will generate how much $ if approved?.. the BOARD ASKING THAT QUESTION TOO?.. well never mind Kate, (what’s a measly 2.5 mil in R&D)... you were busy providing face time @ NIDA, as you said: “ And I, myself, have been participating in opioid summit with leadership from NIDA, from Health and Human Services, from FDA and NIH. That work continues”, so it’s all OK.. was Marc even at the conference call? .. sounds as though he was patched in from somewhere else… I hope someone buys the intellectual property before these people spend all the cash… IMHO, Braeburn’s strategic emphasis on depot will not net Apple Tree ROI given the competitive landscape currently against ALKS & INVYY, but that’s their problem.. TTNP needs to step it up & wake up to move beyond Braeburn & Apple Tree
News 
Market Data 
Discover 
AI
